期刊文献+

TRAIL及其受体在膀胱癌中的表达及相关性研究

Expression and correlation of TRAIL and its receptors in bladder cancer
下载PDF
导出
摘要 目的:观察肿瘤坏死因子相关诱导凋亡配体(TRAIL)及其受体DR4、DcR1在膀胱癌组织及正常膀胱黏膜中的表达,并探讨其与临床病理特征间的相关性。方法:采用免疫组织化学PV9001二步法检测64例膀胱癌石蜡标本及14例正常膀胱组织中的TRAIL、DR4、DcR1的表达,结合患者病理资料,分析其与患者临床病理特征之间的关系。结果:TRAIL、DR4在膀胱癌组织中的表达较正常组织中的表达低,DcR1表达与之相反(P<0.05)。进一步统计分析得出TRAIL、DR4在高分化膀胱癌中表达较中低分化癌高,DcR1与之相反(P<0.05)。TRAIL、DR4、DcR1的表达与性别、年龄、临床分期及是否淋巴转移等病理特征无关(P>0.05)。结论:TRAIL、DR4、DcR1在膀胱癌组织及正常组织中的表达具有统计学差异,并且与病理分级具有一定的相关性,与其他临床病理特征无关。 Objective To observe the tumor necrosis factor related apoptosis inducing ligand (TRAIL) and its re-ceptor DR4 and DcRl expression in bladder carcinoma and normal bladder mucosa,and to investigate its correlation with the clinicopathological features. Methods : Immunohistochemistry PV9001 two step method was used to detect 64 cases of bladder cancer specimens and 14 cases of normal bladder tissue in TRAIL, DR4, DcR1 , combined with the pathological data of patients,analyze their relationship with the clinicopathological characteristics of patients. Results:The expression of DR4 and TRAIL in bladder cancer tissues was lower than that in normal tissues,but DcRl expres-sion was opposite (P 〈0. 05) . Further statistical analysis showed that DR4 and TRAIL expression in highly differenti-ated bladder cancer was lower than that of moderately and pcorly differentiated carcinoma, and DcRl was the opposite (P 〈0. 05) . Expression of TRAIL,DR4 and DcRl was not related to gender,age,clinical stage,lymph node metasta-sis and other pathological features(P 〉0. 05). Conclusion: The expression of TRAIL, DR4, DcRl in bladder cancer tissue and normal tissue is statistically significant, and has a certain correlation with pathological grading, which is not related to other clinical pathological characteristics.
出处 《现代肿瘤医学》 CAS 2017年第17期2760-2764,共5页 Journal of Modern Oncology
基金 国家自然科学基金(编号:81372733) 兰州大学院内博士科研基金(编号:ynbskyjj2015-1-17)
关键词 TRAIL 免疫组化 表达 相关性 TRAIL, immunohistochemistry, expression, correlation
  • 相关文献

参考文献3

二级参考文献14

  • 1Kim Y, Seol DW. TRAIL, a mighty apoptosis inducer[J].Mol Cells. 2003,15(3) :283-293.
  • 2Liu XS, Zhu Y, Han WN, et al. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1 and DcR2[J]. Hybrid hybridomics. 2003,22(2):121-123.
  • 3Krieg A, Krieg T,Wenzel M, et al. TRAIL-beta and TRAIL-gama:two novel splice variants of the human TNF-related apoptosis inducing ligand (TRAIL) without apoptosis potential[J]. Br J Cancer. 2003,88(6) :918-927.
  • 4Takeda K, Yarnaguchi N, Akiba H, et al. Induction of Tumorspecific T Cell Immunity by Anti-DR5 Antibody Therapy[J]. The Journal of Experimental Medidne. 2004,199(4): 437-448.
  • 5Leverkus M, Neumann M, Mengling T, et al. Regulation of tumor necrosis factor related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes [J].Cancer Res,2000,60(3) :553-559.
  • 6Chawla-Sarkar M, Bae SI, Reu FJ, et al. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo-2L/TRAIL- induced apoptosis[J]. Cell Death Differ, 2004,11 (8) :915-923.
  • 7Kim K,Clin Cancer Res,2000年,6卷,335页
  • 8Kemp TJ,Kim J S,Crist SA, et al. Induction of necrotic tumor cell death by TRAIL/Apo-2L[J]. Apoptosis, 2003,8 : 587.
  • 9Wajant H, Pfizenmaier K, Scheurich P, TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy[J]. Apoptosis, 2002,7 :449.
  • 10Srivastava RK. Intracellular mechanisms of TRAIL and its role in cancer therapy[J]. Mol Cell Biol Res Commun, 2000,4:67.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部